Literature DB >> 22546998

Choroidal neovascularization and bevacizumab therapy in Aicardi syndrome.

Adam S Wenick, Daniel M Paskowitz, M Zain Tauqir, Quan Dong Nguyen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22546998     DOI： 10.1007/s00417-012-2025-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Progressive pigmentation of chorioretinal lesions in aicardi syndrome.

Authors:  Luis H Ospina; Harish Nayak; Andrew Q McCormick
Journal:  Arch Ophthalmol       Date:  2004-05

2.  Aicardi syndrome: chorioretinal lacunae without corpus callosum agenesis.

Authors:  Diana Iturralde; Catherine B Meyerle; Lawrence A Yannuzzi
Journal:  Retina       Date:  2006-10       Impact factor: 4.256

3.  Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.

Authors:  Wei-Chi Wu; Po-Ting Yeh; San-Ni Chen; Chung-May Yang; Chi-Chun Lai; Hsi-Kung Kuo
Journal:  Ophthalmology       Date:  2010-07-29       Impact factor: 12.079

4.  Aicardi's syndrome. A clinicopathologic study.

Authors:  R G McMahon; R A Bell; G R Moore; S K Ludwin
Journal:  Arch Ophthalmol       Date:  1984-02

Review 5.  Aicardi syndrome.

Authors:  Jean Aicardi
Journal:  Brain Dev       Date:  2005-04       Impact factor: 1.961

6.  Bevacizumab for the treatment of pediatric retinal and choroidal diseases.

Authors:  Robert A Sisk; Audina M Berrocal; Thomas A Albini; Timothy G Murray
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2010-08-30

7.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

8.  Role of ocular involvement in the prediction of visual development and clinical prognosis in Aicardi syndrome.

Authors:  A V Menezes; T L Lewis; J R Buncic
Journal:  Br J Ophthalmol       Date:  1996-09       Impact factor: 4.638

9.  Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.

Authors:  Julia L Glade Bender; Peter C Adamson; Joel M Reid; Lu Xu; Sylvain Baruchel; Yuval Shaked; Robert S Kerbel; Erin M Cooney-Qualter; Diana Stempak; Helen X Chen; Marvin D Nelson; Mark D Krailo; Ashish M Ingle; Susan M Blaney; Jessica J Kandel; Darrell J Yamashiro
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

10.  Aicardi syndrome: follow-up investigation of Swedish children born in 1975-2002.

Authors:  L Palmér; B Zetterlund; A-L Hård; K Steneryd; M Kyllerman
Journal:  Neuropediatrics       Date:  2007-08       Impact factor: 1.947
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.